bpc 157 clinical trial human case report Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing What is BPC-157? | Everything

In many patients with severe primary IGF-I deficiency (SPIGFD) defined by low IGF-I (less than 3 SDS or the 2.5 th percentile), severe short stature (Height SDS less than 3), normal GH secretion and absence of acquired insensitivity to GH (discussed below) genetic defects may be absent

This reduces stiffness, improves durability, and lowers the risk of reinjury

The data is also usually kept in house, so theres not a wider knowledge of the problem

doi: Nikhil Vasireddi, Henrik Hahamyan, Salata MJ, et al

These trials included both single-dose pharmacokinetic studies and long-term efficacy trials extending up to 24 weeks of continuous administration